SynthesisFrontiers in cardiovascular medicine2026
Immunoadsorption and subsequent immunoglobulin G replacement (IA/IG) in patients with dilated cardiomyopathy: a systematic review and meta-analysis.
Synthesis in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dilated cardiomyopathy (DCM) is a refractory cardiac disease with significant morbidity and mortality. Although immune adsorption combined with immunoglobulin G replacement therapy (IA/IG) has shown potential in treating DCM, only small-scale clinical trials have been reported. Its efficacy and safety characteristics still need to be further systematically evaluated. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA 2020 guidelines. A comprehensive search of PubMed, Embase, Web of Science, and the Cochrane Library was performed up to July 1, 2025. Clinical studies on IA/IG treatment for DCM were included. The primary outcome was the left ventricular ejection fraction (LVEF) change. Secondary outcomes included left ventricular end-diastolic dimension (LVEDD), NYHA functional class, N-terminal pro-brain natriuretic peptide (NT-proBNP), and VO2 peak. Study quality and risk of bias were assessed using the Cochrane ROB 2.0 and ROBINS-I tools. Sensitivity analysis was taken into consideration to determine the stability of the results. This review was registered with PROSPERO (CRD420251104796). Results: Eighteen studies (2 RCTs and 16 non-RCTs) involving 809 participants were included. IA/IG therapy significantly improved LVEF [mean difference (MD) = 7.71%, 95% CI: 6.18-9.24, Conclusion: Systematic reviews and meta-analyses suggest that IA/IG therapy may improve cardiac function and quality of life in patients with DCM. However, the number of RCTs included in the study is limited, so these results should be interpreted with caution. Further high-quality, large-scale trials are warranted to establish standardized treatment protocols and confirm the long-term benefits of IA/IG therapy. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard, PROSPERO CRD420251104796.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.